Wallace Advisory Group LLC Boosts Stock Position in Zoetis Inc. (NYSE:ZTS)

Wallace Advisory Group LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 37.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,476 shares of the company’s stock after buying an additional 1,228 shares during the period. Wallace Advisory Group LLC’s holdings in Zoetis were worth $776,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in ZTS. Aveo Capital Partners LLC purchased a new stake in shares of Zoetis during the fourth quarter worth about $225,000. Gryphon Financial Partners LLC increased its stake in Zoetis by 11.8% during the 4th quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after buying an additional 322 shares in the last quarter. Evoke Wealth LLC raised its holdings in shares of Zoetis by 14.1% during the fourth quarter. Evoke Wealth LLC now owns 1,675 shares of the company’s stock valued at $331,000 after acquiring an additional 207 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Zoetis by 0.7% in the fourth quarter. California State Teachers Retirement System now owns 740,935 shares of the company’s stock valued at $146,238,000 after acquiring an additional 5,031 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its stake in shares of Zoetis by 8.7% in the fourth quarter. Jones Financial Companies Lllp now owns 25,213 shares of the company’s stock worth $4,976,000 after acquiring an additional 2,024 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on ZTS. BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Finally, Stifel Nicolaus increased their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus price target of $220.38.

Zoetis Price Performance

Zoetis stock opened at $194.81 on Monday. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a market cap of $88.26 billion, a P/E ratio of 37.54, a PEG ratio of 2.99 and a beta of 0.88. The company has a 50-day moving average price of $186.04 and a 200 day moving average price of $174.78. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter last year, the firm earned $1.41 EPS. The business’s revenue was up 8.3% compared to the same quarter last year. Sell-side analysts anticipate that Zoetis Inc. will post 5.84 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.